These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37116720)

  • 1. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
    Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
    Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
    Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.
    Sood S; Mandell J; Watane A; Friedman S; Parikh R
    JAMA Ophthalmol; 2022 Jul; 140(7):716-723. PubMed ID: 35708679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
    Kaiser PK; Schmitz-Valckenberg MS; Holz FG
    Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M; van der Reis MI; Webers CA; Schouten JS
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Use.
    Glasser DB; Parikh R; Lum F; Williams GA
    Ophthalmology; 2020 Dec; 127(12):1688-1692. PubMed ID: 32544559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Anti-Vascular Endothelial Growth Factor Original Medicare Part B Claims in the United States, 2014-2019.
    Desai S; Sekimitsu S; Rossin EJ; Zebardast N
    Ophthalmic Epidemiol; 2024 Oct; 31(5):468-477. PubMed ID: 38315793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview.
    Viola P; Testa V; Ferro Desideri L; Di Cello L; Rutigliani C; Vagge A; Nicolò M; Cian R; Traverso CE
    Drugs Today (Barc); 2021 Nov; 57(11):689-697. PubMed ID: 34821882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
    Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
    JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
    Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
    Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
    Baisiwala S; Bundorf MK; Pershing S
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of International Pricing Index Models on Anti-Vascular Endothelial Growth Factor (VEGF) Drug Costs in the United States.
    Choi S; Chen EM; Chen D; Sridhar J; Parikh R
    Semin Ophthalmol; 2022 Jan; 37(1):23-28. PubMed ID: 33822670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study.
    Spini A; Giometto S; Donnini S; Posarelli M; Dotta F; Ziche M; Tosi GM; Girardi A; Lucenteforte E; Gini R; Etminan M; Virgili G
    Am J Ophthalmol; 2023 Apr; 248():45-50. PubMed ID: 36410468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.